1-5 of 5
Drew Rasco
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors

Nehal J. Lakhani, Drew Rasco, Hengbang Wang, Lichuang Men, Eric Liang, Tommy Fu, Mary C. Collins, Ping Min, Yan Yin, Matthew S. Davids, Dajun Yang, Yifan Zhai
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 506–521.
https://doi.org/10.1158/1078-0432.CCR-23-1525
Published: 01 February 2024
View article titled, First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Open the PDF for First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4158.
https://doi.org/10.1158/1078-0432.CCR-22-2320
Published: 15 September 2022
View article titled, Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Open the PDF for Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors in another window
Journal Articles

Correction: First-in-Class Anti-Immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1734.
https://doi.org/10.1158/1078-0432.CCR-22-0564
Published: 14 April 2022
View article titled, Correction: First-in-Class Anti-Immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Open the PDF for Correction: First-in-Class Anti-Immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors in another window
Journal Articles

First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 57–70.
https://doi.org/10.1158/1078-0432.CCR-21-2160
Published: 01 January 2022
View article titled, First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Open the PDF for First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, S. Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino, Kevin Gergich, Liliana Delgado, Adil Daud, Jill A. Lindia, Xiaoyun Nicole Li, Robert H. Pierce, Jennifer H. Yearley, Dianna Wu, Omar Laterza, Manfred Lehnert, Robert Iannone, Anthony W. Tolcher
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (19): 4286–4293.
https://doi.org/10.1158/1078-0432.CCR-14-2607
Published: 30 September 2015
View article titled, Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data